Neose Technologies, Inc. engages in the development and commercialization of therapeutic proteins in the United States. It offers products based on the GlycoPEGylation technology that involves the use of enzymes to attach PEG to carbohydrate structures on proteins. Its therapeutic protein candidates in development include GlycoPEG-EPO (NE-180), in phase-II trials, for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure; GlycoPEG-GCSF, in phase-I trials, for neutropenia associated with myelosuppressive chemotherapy; and GlycoPEG-FVIIa for the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors. It has collaborations with BioGeneriX AG; MacroGenics, Inc.; and Novo Nordisk A/S. The company was founded in 1989 and is based in Horsham, Pennsylvania.